Your browser is no longer supported. Please, upgrade your browser.
Settings
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E3080.71 EPS (ttm)0.01 Insider Own0.20% Shs Outstand2.43B Perf Week-0.67%
Market Cap104.65B Forward P/E15.59 EPS next Y2.77 Insider Trans0.00% Shs Float2.42B Perf Month-0.76%
Income40.20M PEG308.07 EPS next Q0.80 Inst Own9.10% Short Float0.29% Perf Quarter1.04%
Sales32.66B P/S3.20 EPS this Y204.10% Inst Trans5.62% Short Ratio2.49 Perf Half Y7.86%
Book/sh0.31 P/B139.13 EPS next Y6.47% ROA0.10% Target Price48.67 Perf Year19.38%
Cash/sh2.50 P/C17.26 EPS next 5Y10.00% ROE0.90% 52W Range35.52 - 45.07 Perf YTD13.01%
Dividend2.20 P/FCF- EPS past 5Y40.20% ROI41.40% 52W High-4.30% Beta0.89
Dividend %5.10% Quick Ratio0.60 Sales past 5Y-3.40% Gross Margin66.60% 52W Low21.42% ATR0.60
Employees101192 Current Ratio0.90 Sales Q/Q10.90% Oper. Margin5.30% RSI (14)46.89 Volatility1.26% 1.13%
OptionableYes Debt/Eq34.12 EPS Q/Q-392.80% Profit Margin0.10% Rel Volume0.91 Prev Close42.90
ShortableYes LT Debt/Eq26.30 EarningsOct 26 Payout- Avg Volume2.84M Price43.13
Recom2.00 SMA20-0.39% SMA50-1.49% SMA2005.25% Volume2,588,026 Change0.54%
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Sep-30-16 06:45PM  Glaxo paying $20M to resolve SEC charges of China bribery
05:05PM  [$$] GlaxoSmithKline to Pay $20 Million to Settle SEC Bribery Probe at The Wall Street Journal
03:04PM  GlaxoSmithKline to pay $20 mln to settle U.S. foreign bribery case Reuters
02:18PM  Glaxo to Pay $20 Million SEC Fine Over Bribing Chinese Officials
02:18PM  Glaxo to Pay $20 Million SEC Fine Over Bribery in China at Bloomberg
02:18PM  GlaxoSmithKline to pay $20 mln to settle foreign bribery related charges Reuters
01:25PM  The Highest-Yielding Drug Stocks at Motley Fool
11:05AM  Which Pfizer Products Reported Declining Sales?
11:05AM  Understanding Strong Growth Trends in Insulin and Novo Nordisks Profitability
10:05AM  Novo Nordisk Continues to Be a Leader in the Global Insulin Market
08:05AM  Why Novo Nordisk Expects Double-Digit Growth in Diabetes Care in 2016
Sep-29-16 03:04PM  Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk
09:52AM  GlaxoSmithKline (GSK) Stock Down, McNamara Named CEO of Consumer Healthcare Unit
08:40AM  Glaxo Appoints Brian McNamara Chief of Consumer Health Division at Bloomberg
08:20AM  After CEO move, GSK picks ex-Novartis exec to head consumer unit
04:16AM  Aspen Sinks to Four-Month Low as Volumes Surge After Glaxo Sells
Sep-28-16 03:14PM  Ariel Funds Comments on GlaxoSmithKline plc
01:58PM  John Rogers' Ariel Global Fund 2nd Quarter Commentary
12:21PM  Glaxo Sells Stake in South Africas Aspen for $619 Million at Bloomberg
10:05AM  Teva Is Well Placed to Dominate the European Generics Market
09:55AM  GlaxoSmithKline Vaccines for Malaria, Zika Make It a Likely Winner
09:30AM  The Zacks Analyst Blog Highlights: General Electric, GlaxoSmithKline and McDonald
09:29AM  Battle of the Pharmaceutical Bigwigs: GlaxoSmithKline vs. Pfizer
08:03AM  3 Stocks to Avoid in Healthcare at Motley Fool
Sep-27-16 11:45AM  New Research Reports for GE, McDonald's & GSK
Sep-26-16 05:50PM  Frances Essilor Said to Hire Glaxos Halper as Head of M&A at Bloomberg
09:33AM  The Internet of Medical Things: 6 Stocks in Focus
08:56AM  Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.
06:25AM  Apple iPhone Calling Big Pharma: We Can Help You Develop Better Drugs at Motley Fool
Sep-25-16 11:10AM  3 Bold Bets on the Future of Biotechnology at Motley Fool
Sep-24-16 10:00AM  5 Stocks to Sell Now Before It's Too Late
Sep-23-16 07:54AM  [$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience at Financial Times
07:15AM  Coverage initiated on GlaxoSmithKline by Piper Jaffray
Sep-22-16 11:12AM  Hard to swallow: emerging markets get tougher for drugmakers
10:48AM  The Pros and Cons of Buying Gilead Sciences Stock at Motley Fool
10:45AM  HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target
Sep-21-16 10:05AM  Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment
01:01AM  Inside the 10-Year, $1 Billion Battle for the Next Critical Antibiotic at Bloomberg
Sep-20-16 07:38PM  PRESS DIGEST- Financial Times - Sept 21 Reuters
03:30PM  Medecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix at Insider Monkey
11:25AM  GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive at Forbes
11:05AM  Big Pharmas Latest Breakthrough: Choosing Its First Female CEO
10:46AM  Breaking the mould: GSK picks Big Pharma's first female CEO
09:05AM  GlaxoSmithKline (GSK) Stock Lower, Names Walmsley CEO
07:14AM  Glaxo CEO's Potential Achilles Heel at Bloomberg
07:00AM  GlaxoSmithKline Appoints Insider Walmsley as new CEO
06:22AM  5 Things You Must Know Before the Market Opens Tuesday
06:10AM  GlaxoSmithKline names insider Emma Walmsley as new CEO
05:04AM  UPDATE 2-GlaxoSmithKline names insider Emma Walmsley as new CEO Reuters
04:16AM  GSK names Emma Walmsley as new chief executive
02:13AM  GlaxoSmithKline names consumer head Walmsley new CEO
02:04AM  Glaxo Names Emma Walmsley as New CEO to Succeed Andrew Witty at Bloomberg
Sep-19-16 05:04PM  British pharma group GSK picks new CEO AFP
11:01AM  The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution at Motley Fool
08:04AM  Roche Goes Up against Bristol-Myers Squibb in Oncology Drug Space
07:34AM  GSK cuts vaccine price for refugees, bowing to pressure
Sep-18-16 06:46PM  GSK CEO: Pharma firms need to be empathetic
Sep-16-16 12:42PM  Drugmakers Must Report Clinical Trial Results Once Kept Secret
11:15AM  Drugmakers Must Report Clinical Trial Results Once Kept Secret at Bloomberg
09:05AM  Epizyme Receives Milestone from Glaxo for Lymphoma Drug
08:04AM  Roches Oncology Wheelhouse Stacked with Competitive Drugs
Sep-15-16 03:44PM  Bullish on SoftBank, ASML, Royal Dutch Shell and GlaxoSmithKline
02:21PM  4 Foreign Stocks to Fire Up Your Portfolio at TheStreet
11:04AM  Sanofis Chase for Zika Virus Vaccine Could Drive Its Share Price
10:27AM  Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Sep-14-16 05:37PM  GSK's candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM PR Newswire
05:00PM  GSK shingles vaccine remains effective after four years -study Reuters
10:42AM  You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne at Motley Fool
08:27AM  How GlaxoSmithKline Took Its Medicine at Forbes
06:56AM  Glaxo, Astra Lead U.K. Drugmakers to Seek Continued EU Access at Bloomberg
Sep-13-16 11:04AM  GSK Optimistic about Future of Its Consumer Healthcare Segment
10:09AM  Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU
10:04AM  GlaxoSmithKline Giving a Shot to Its Vaccines Business
08:04AM  Performance of GSKs Global Pharmaceuticals Franchises Mixed
06:50AM  Analysts Hit Reset Button On GlaxoSmithKline
Sep-12-16 11:04AM  GlaxoSmithKlines Combo Treatment for HIV Faces Stiff Competition
10:04AM  Whats the Problem with GSKs Pharmaceutical Segment?
09:54AM  The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working at Motley Fool
08:05AM  Of GSKs Business Segments, This One Is the Sales Laggard
04:19AM  Aspen to Buy Glaxo Drugs for $372 Million as Deal Spree Goes On
03:50AM  GSK sells anaesthetics to Aspen for up to $370 mln Reuters
Sep-11-16 08:09AM  My 3 Biggest Stock Holdings at Motley Fool
Sep-09-16 06:04PM  What Investors Can Glean from GlaxoSmithKlines Revenue Trend
04:04PM  GlaxoSmithKlines Fundamentals Show It Has Lots of Room to Run
Sep-08-16 11:29AM  Merck's Lung Cancer Drug Keytruda Under Priority Review
10:53AM  Glaxo Proposes Biopreparedness Unit for Outbreaks Like Zika at Bloomberg
Sep-07-16 05:44PM  Europe: New safe haven?
03:28PM  Gilead Sciences: Wait, You're Not Going to Split the Company in Two? at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands
Sep-06-16 10:32AM  Glaxo Bexsero Meningitis B Immunization Shows Positive Data
09:45AM  GSK's triple drug cuts flare-ups in chronic lung disease Reuters
09:45AM  GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress Business Wire
08:00AM  6 Drug Stocks in Focus as Zika Virus Fear Spreads
Sep-04-16 02:05PM  How Google Plans to Reinvent Healthcare at Motley Fool
05:00AM  Positive Results From the COPD Salford Lung Study Published in the NEJM and Presented at European Respiratory Congress Business Wire
Sep-02-16 02:45AM  AstraZeneca, Glaxo Explore Prevention Potential of Asthma Shots at Bloomberg
Sep-01-16 11:04AM  Why Pfizers Vaccines Business Is Declining
08:04AM  How Analysts See United Therapeutics Continued Performance
Aug-31-16 10:35AM  4 Off-the-Radar Analyst Picks Yielding More Than 4% at 24/7 Wall St.
08:50AM  7 Healthy Dividend Stocks for Quality and Security at Kiplinger
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc has collaboration agreements with Universite de Sherbrooke and Pfizer Inc.; development agreement, and R and D collaboration with Propeller Health; R and D collaboration agreement with Valneva SE; and collaboration and license agreement with Idera pharmaceuticals, Inc. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.